Eva Harris and Janet Smith join TWiV to discuss how an antibody against dengue virus NS1 protein blocks endothelial dysfunction and the potential of treating infections by multiple flaviviruses.
Theodora and Paul return to TWiV to explain how they quickly pivoted their retrovirus laboratories towards SARS-CoV-2, their work on the antibody response to infection and its durability, and the emergence of variants with increased resistance to neutralization.
In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
In Daniel Griffin’s final clinical report for 2020, he summarizes what we have learned about the clinical management of COVID-19 patients in the past year.
Daniel Griffin provides his weekly clinical report on COVID-19, including thoughts on the first immunizations with Pfizer mRNA vaccine, the anticipated EUA for the Moderna vaccine, whether the vaccine prevents infection, not just disease, monoclonal antibody therapy, and much more.
Daniel Griffin provides his weekly clinical report on COVID-19, including new post-exposure guidelines from CDC, clinical trials of Remdesivir and convalescent plasma, FDA EUA for baricitinib and Regeneron’s monoclonal antibody and more.
Ari and Kishana, two of the founders of Black in Microbiology, join TWiV to discuss the goals of the organization, then we review pauses of J&J and Lilly COVID-19 vaccine trials, preclinical studies of Regeneron’s SARS-CoV-2 monoclonal antibody cocktail, reinfection of a patient in Nevada, and listener questions.
Daniel Griffin discusses President Trump’s case of COVID-19, including the clinical course, the medications he received and why, and expectations for the next few weeks.
Ralph Baric returns to TWiV to provide an update on the COVID-19 resurgence in the US, monoclonal antibodies, antiviral drugs, vaccines, immunity and reinfection, reopening schools, and what will happen this fall.
The Autonomous CollecTWiVe reveal two effective treatments for Ebolavirus infection, how a virus in a fungus confers heat tolerance to a plant, and dampened inflammation as a mechanism for bat tolerance to viral infection.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.